over that of the adult control group (
p = 0.001) (Figure
2D).
3.2 Content of carbonylated proteins increased after RAD140 supplementation
Protein carbonylation, one of the most harmful irreversible oxidative protein modifications, is considered a major hallmark of oxidative stress-related disorders.
44,
45 As with the frailty index scores, individual data is depicted for visualization (Figure
3B,E,H) but due to the small sample size of RAD mice that survived, the young and adult RAD groups were combined for statistical analyses (Figure
3C,F,I). The young control group had lower levels of protein carbonylation in the kidney versus the adult control group (
p = 0.041), while no differences were observed between these groups for the liver (
p = 0.640) and tibialis anterior muscle (
p = 0.787). The RAD group had more protein carbonylation in the kidney compared to the young (
p < 0.001) and adult (
p < 0.001) control groups (Figure
3A–C). Liver protein carbonyls were also greater in the RAD group compared to the young control group (
p = 0.020) but not the adult control group (
p = 0.076) (Figure
3D–F). Supplementing with RAD140 did not influence protein carbonylation in the tibialis anterior muscle when compared to the young (
p = 0.785) or adult (
p = 0.999) control groups (Figure
3G–I).
FIGURE 3
Open in figure viewerPowerPoint
RAD140 Supplementation increased content of carbonylated proteins in kidney (A–C) and liver (D–F) tissue but not skeletal muscle (G–I). No statistical analyses were completed in panels B, E, and H due to the limited number of mice that survived after RAD supplementation, particularly for the young RAD (
n = 2). Young and adult RAD groups were combined in panels C, F, and I. RAD groups are mice supplemented with RAD140. The left tibialis anterior was used for the skeletal muscle analysis. Protein carbonylation was normalized to the loading control, either actin (kidney) or vinculin (liver, skeletal muscle), and expressed relative to the young control group. The sample size for each group at the study initiation was four; young control, five; young RAD, seven; adult control, seven; adult RAD. Young and adult mice started supplementation at 12 and 68 weeks old, respectively, and continued for 10 weeks. *Significantly different than the young control group (
p < 0.05). #Significantly different than the old control group (
p < 0.05). Data is mean ± standard error of the mean (SEM). DNP, 2,4-dinitrophenyl; LC, loading control.
3.3 Adaptation to eccentric exercise training appeared to be blunted by RAD140
To determine if RAD140 supplementation was able to improve muscle adaptations to eccentric exercise, commonly referred to as the repeated bout effect, isometric tetanic torque of the dorsiflexors was compared between Bouts 1 and 4 (Figure
4A). Specifically, torque measured immediately prior to (Pre) and after (Post) the injury and 7 days into recovery (Day 7) for each bout was analysed. In the young control group, torque production was greater during Bout 4 compared to Bout 1 (
p < 0.001). That is, the young control group became stronger from Bouts 1 to 4 (Figure
4A). No differences were detected between Bouts 1 and 4 within the young RAD, adult control, or adult RAD groups (
p ≥ 0.135). Next, muscle adaptive potential was calculated to assess if changes (or lack thereof) in torque from Bouts 1 to 4 were different between groups (Figure
4B). Essentially, muscle adaptive potential is the percent change in torque between Bouts 1 and 4 for a given time point (i.e., Pre, Post, Day 7). Adaptive potential was greater in the young control group compared to the young RAD, adult control, and adult RAD groups (
p ≤ 0.040), while no differences were observed between the latter three groups (
p ≥ 0.609) (Figure
4B).
FIGURE 4
Open in figure viewerPowerPoint
RAD140 supplementation appeared to blunt the repeated bout effect in young female mice. The ability to respond to eccentric exercise was measured by analysing the dorsiflexor tetanic isometric torque (A) and the percent change in torque (B) between Bouts 1 and 4. Specifically, torque measured immediately prior (Pre) and after (Post) the injury and 7 days into recovery (Day 7) for Bouts 1 and 4 were compared. RAD groups are mice supplemented with RAD140. The sample size for each group ranges between four and seven mice depending on survival (see Figure
2). *Significantly different than the young control group (
p < 0.05). Data is mean ± standard error of the mean (SEM).
3.4 RAD140 did not increase torque in exercised or non-exercised muscles
Because eccentric contractions result in transient reductions in strength that may take over 7 days to recover, tetanic isometric torque of the dorsiflexors was analysed prior to any injuries (Week 1; Pre), 14 days after Bout 3 (Week 5; Pre), and 21 days after Bout 6 (Week 10) (Figure
5). Assessment at these time points allowed us to determine if RAD140 increased strength following eccentric exercise training. No group differences in torque were detected at baseline testing during Week 1 (
p = 0.226). Moreover, despite markers of muscle adaptation being greater in the young control group (Figure
4), torques 14 days after Bout 3 and 21 days after Bout 6 were similar among all the groups (
p ≥ 0.470) (Figure
5). Notably, these measures were only made in mice that were ‘healthy’ enough to complete testing; all the young mice receiving RAD140 either died or had to be euthanized prior to Week 10.
FIGURE 5
Open in figure viewerPowerPoint
RAD140 supplementation did not increase muscle strength in exercised muscle. The tetanic isometric torque of the left dorsiflexors (anterior crural muscles) was assessed at Weeks 1, 5, and 10, representing strength production prior to performing eccentric contractions for that given week. No eccentric contractions were completed at Week 10. Isometric torque values for Weeks 5 and 10 were determined 14- and 21-days following Bouts 3 and 6, respectively (see Figure
1). Data is from mice considered ‘healthy’ and able to complete physiological testing. No young mice receiving RAD survived until Week 10 testing (Figure
2). RAD groups are mice supplemented with RAD140. The sample size for each group ranges between four and seven mice depending on survival (see Figure
2). Data is mean ± standard error of the mean (SEM).
In parallel to measuring the effects of RAD140 supplementation on tetanic isometric torque of the dorsiflexors before and after eccentric exercise training, we also measured tetanic isometric torque of the plantarflexors. The plantarflexors did not perform any eccentric contractions and were simply tested to determine if consuming RAD140 independent of eccentric training improved muscle strength. As with tetanic isometric torque of dorsiflexors, no group differences were observed in tetanic isometric torque of the plantarflexors at Weeks 1, 5 or 10 (
p ≥ 0.091) (Figure
6).
FIGURE 6
Open in figure viewerPowerPoint
Strength in non-exercised muscle did not change after RAD140 supplementation. The tetanic isometric torque of the left plantarflexors (posterior crural muscles) was assessed at Weeks 1, 5 and 10. The plantarflexors did not perform any eccentric contractions and were considered non-exercised. Data is from mice considered ‘healthy’ and were able to complete physiological testing. No young mice receiving RAD survived until week 10 testing (Figure
2). RAD groups are mice supplemented with RAD140. The sample size for each group ranges between four and seven mice depending on survival (see Figure
2). Data is mean ± standard error of the mean (SEM).
4 DISCUSSION
The overall goals of this exploratory study were to determine how long-term RAD140 supplementation influenced muscle adaptability and strength gains following a resistance training regimen and overall health in young and adult female mice. Three primary findings were observed, none supporting our initial hypothesis that RAD140 would be beneficial in young and adult female mice. First, RAD140 supplementation did not increase muscle strength, regardless of training status (i.e., with or without performing eccentric contractions). Second, RAD140 did not improve the muscle's ability to adapt after repeated bouts of eccentric contractions. In fact, RAD140 may have even caused a blunting in muscle adaptation. Third, treatment with RAD140 significantly increased kidney and liver protein carbonylation, frailty index scores, and mortality risk in both young and adult mice. Together, these findings (in female mice) indicate that supplementing with RAD140 at a dose of 5 mg/kg does not effectively increase skeletal muscle resiliency or force production and reduces indices of overall health, suggesting that RAD140 may be more detrimental than beneficial in delaying or preventing sarcopenia.
Based on previous studies that used RAD140,
28 we hypothesized that long-term supplementation of RAD140 would increase muscle strength, particularly in adult female muscle that exhibits a blunting in exercised-induced muscle adaptations (Figure
4; young control vs. adult control). Our results contradict our hypothesis. In fact, adult mice supplemented with RAD140 were no better than adult control mice as measured by the muscle's adaptive potential or tetanic isometric torque in exercised or non-exercised legs (Figures
4-
6). The finding that RAD140 appeared to blunt the muscle's ability to adapt in young mice further supported our decision to reject our initial hypothesis. Although this was the first study to complete long-term RAD140 treatment, two other studies assessed changes in muscle mass after short-term RAD140 supplementation.
28,
46 Using doses ranging from 0.1 to 30 mg/kg for 11 days, Miller et al.
28 demonstrated that muscle mass of the levator ani bulbocavernosus increased by approximately 160–310 mg in immature male rats. Similarly, Puskas et al.
46 reported that in young male rats, the cross-sectional area (CSA) of the plantaris was greater after 14 days of approximately 2 mg/kg RAD140 supplementation yet was not sufficient to significantly alter the wet mass of the plantaris or soleus muscles when compared to the control group. In the same study, the contralateral muscles (i.e., plantaris and soleus) were subjected to functional overload through removal of the gastrocnemius to determine if RAD140 administration could increase muscle hypertrophy to a greater extent than functional overload alone (i.e., control group). However, no group differences were observed among wet masses of these muscles or plantaris CSA. These data, taken as a whole, suggest that using RAD140 to increase muscle wet mass, fibre CSA, or strength in either the basal or stressed states (e.g., exercise, functional overload) has little to no benefit.
In contrast to RAD140, supplementation with other SARMs (e.g., LGD-2226, GSK2881078, and LY305) have been reported to increase muscle mass and strength under basal
47 and stressed
48 conditions while also enhancing recovery of strength following skeletal muscle injury.
49 Using a mouse model of Duchenne muscular dystrophy (the
mdx mouse), Cozzoli et al.
50 determined that the SARM GLPG0492 protects the extensor digitorum longus muscle from damage (i.e., force drop) after 10 eccentric contractions. Although not likely a direct mechanism for attenuating eccentric contraction-induced force drop in the
mdx mouse, GLPG0492 has been reported to decrease muscle catabolism by inhibiting ubiquitin ligases.
51 Testosterone and other anabolic steroid analogues targeting the AR have also been reported to improve muscle mass and strength recovery.
52 For example, White et al.
53 determined that following a chemical-induced injury (0.75% bupivacaine solution), male mice treated with nandrolone decanoate, an analogue of testosterone, showed enhanced muscle recovery of the tibialis anterior after 42 days, with strength (i.e., tetanic isometric torque) being 40% greater than injured controls. Mechanistically, SARMs and other AR agonists are thought to enhance activation of resident satellite cells to increase the muscle's regenerative properties.
54 These positive results indicate that AR signalling may indeed cause hypertrophy and enhance recovery following injury; therefore, therapeutics that target ARs are likely warranted. However, there is currently no available literature comparing how supplementation of RAD140 and other SARMs may differ, making it difficult to evaluate the efficacy of all AR-related therapeutics.
We also hypothesized that long-term RAD140 supplementation would, in essence, rejuvenate adult mice to a younger phenotype. However, again our results strongly contradicted this hypothesis. Long-term RAD140 consumption appeared to prematurely age both young and adult mice, as measured by frailty index scores and risk of early mortality (Figure
2). These results were unplanned and unexpected, and
--
k so rite to hate 3/4 but quickly searched and ya one is just weak.. and dumb but actually thinks they know me from somewhere. but brain fog and retardation.
and his english is not like mine (despite being a white european so). so, possibly a little too harsh to think fk hmi. but glad i got off discord for a bit and didn't tell him off. they genuiniely saw others call me spam,and their rodent brain could not comprehend that in fact they're spam, and I'm just lovely.
So, i wish that guy well. But the (more or less) "fuck you's" (elaborately done), to the others. Yeah that stands.